Playback speed
1×
Subtitles
Share post
Share post at current time
0:00
/
0:00
Transcript
0:00
SPEAKER 3
Welcome back to the Drug Development Letter and Plenary Session, the Post-Esmo Highlights, brought to you by Timothy Olivier, friend of the show. People have said the greatest guest host of Plenary Session. So, Timothy, it's good to see you.
0:13
SPEAKER 1
Hi, Vinay. Good to see you. Good to see you all. We are recording live. In front of a live studio audio.
0:18
SPEAKER 3
Yeah, live. All right. What do you got for us? Post-Esmo. We got to do the wrap-up.
1
1

Special post-ESMO 2024 edition !

Timothee Olivier and I discuss the top ESMO 2024 abstracts!
Vinay Prasad
and
Timothée Olivier
Nov 03, 2024
1
1
Share
Transcript

The Drug Development Letter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

13 Likes∙
1 Restack

Discussion about this video

Sahar van Waalwijk
Nov 4

I was wondering why the results of NIAGARA are not even as good as the the adjuvant CheckMate 274. The rate of subsequent immunotherapy in CM-274 was as low as 26%...so let’s see how NIAGARA flows...

Expand full comment
Reply
Share
The Drug Development Letter
The Drug Development Letter
Authors
Vinay Prasad
Timothée Olivier
Recent Posts
CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making
 • Timothée Olivier
The CABINET study
 • Vinay Prasad
RANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.
 • Timothée Olivier
Special ESMO 2024 edition !
 • Vinay Prasad and Timothée Olivier
Driver mutation lung cancer
 • Vinay Prasad
Special post-ASCO 2024 edition !
 • Vinay Prasad and Timothée Olivier
ASCO pre-game show
 • Vinay Prasad